Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4256963 | 0.88 | MEN1 (0.64) | MEN1KMT2A | |
| SCHEMBL3641085 | 0.87 | RAB9A (0.83) | LMNAGAAMAPTRAB9AMEN1 | |
| SCHEMBL3642861 | 0.84 | RAB9A (0.68) | LMNAGAAMAPTRAB9A | |
| SCHEMBL3646031 | 0.83 | — | — | |
| SCHEMBL1455286 | 0.80 | KMT2A (0.90) | LMNAGAAMAPTRAB9AMEN1 | |
| SCHEMBL3644090 | 0.79 | LMNA (0.58) | LMNAGAAMAPTRAB9AMEN1 | |
| SCHEMBL3645711 | 0.78 | JAK2 (0.64) | — | |
| SCHEMBL3645551 | 0.78 | — | — | |
| SCHEMBL28809368 | 0.78 | MEN1 (0.64) | LMNAGAAMAPTRAB9AMEN1 | |
| SCHEMBL3638996 | 0.78 | MAPT (0.76) | LMNAGAAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2182935-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |